Peter Vuylsteke

PARP inhibitors: Synthetic lethality in the clinic

Infrared molecular fingerprinting of blood-based liquid biopsies for the detection of cancer

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer

Role of Positron Emission Tomography for the Monitoring of Response to Therapy in Breast Cancer

Breast cancer

Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer

Resolution of Cancer-Promoting Inflammation: A New Approach for Anticancer Therapy

PARP inhibitor combination therapy

PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions

Ovarian cancer

Olaparib: First Global Approval

Liquid biopsy enters the clinic — implementation issues and future challenges

Molecular and protein markers for clinical decision making in breast cancer: Today and tomorrow

Pancreatic cancer

The causes of porotic hyperostosis and cribra orbitalia: A reappraisal of the iron‐deficiency‐anemia hypothesis

Caffeine and novelty: Effects on electrodermal activity and performance

Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer

Inflammation and tumor progression: signaling pathways and targeted intervention

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Drug development in the era of precision medicine

Persistent B19 Parvovirus Infection in Patients Infected with Human Immunodeficiency Virus Type 1 (HIV-1): A Treatable Cause of Anemia in AIDS

PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies

Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention

Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

The PI3K Pathway in Human Disease

Using sulfuramidimidoyl fluorides that undergo sulfur(vi) fluoride exchange for inverse drug discovery

Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects

Parvovirus B19

Contraceptive use among women with inflammatory bowel disease: A systematic review

The MAPK pathway across different malignancies: A new perspective

Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer

Human Parvovirus B19

Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas

New Strategies in the Treatment of Ovarian Cancer: Current Clinical Perspectives and Future Potential

U.S. Medical Eligibility Criteria for Contraceptive Use, 2016

Meta-Analysis of Randomized Controlled Trials for the Incidence and Risk of Treatment-Related Mortality in Patients With Cancer Treated With Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors

Reactive Oxygen Species (ROS)-Based Nanomedicine

Erythrocyte P Antigen: Cellular Receptor for B19 Parvovirus

Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: A study in 108 patients by the Belgian Gynaecological Oncology Group

Case of megaloblastic anemia caused by intestinal taeniasis

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial

¹⁸F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO

Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial

Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study

Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer

Ischemic Colitis in a Patient with Crohn’s Disease Taking an Oral Contraceptive and an Ergotamine Alkaloid

[Acute secondary and transitory erythroblastopenia in kwashiorkor under treatment].

Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): A randomized, open-label phase II study.

Genomic grade: Feasibility in routine practice and influence on treatment decision in early breast cancer.

Recurrences after highly selective vagotomy in refractory and non-refractory duodenal ulcer disease.